Recruiting

Testing a new cancer treatment alone and with other immunotherapies

Plain-English translation of NCT07070232 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new investigational treatment called in people with advanced solid tumors (cancers that have spread). The study will evaluate whether the medication is safe and works well when given on its own, and whether it works even better when combined with another investigational treatment called . Researchers are also testing different doses to find the best balance between effectiveness and side effects.

Many people with advanced cancer have limited treatment options, especially after standard therapies stop working or become too hard on the body. This trial aims to see if this new medication could offer hope for patients whose cancer has progressed despite previous treatments.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with advanced solid tumors that have spread or come back after previous treatment
you have measurable disease that can be seen on scans or imaging tests
your cancer has progressed despite at least one prior line of standard therapy
you are in generally good health with adequate organ and bone marrow function
you can provide a tumor tissue sample (from a previous biopsy or new biopsy) for testing

You likely don't qualify if…

you are pregnant or breastfeeding
you have severe organ dysfunction or bone marrow problems
you are unable or unwilling to provide a tumor tissue sample
you have active infections or certain other serious medical conditions that would make participation unsafe

What participation looks like

Depending on which part of the study you join, you will either receive alone or combined with . You will be randomly assigned to receive one of two dose levels. You will have regular clinic visits for blood tests, scans, and checkups to monitor how you are tolerating the medication and how your cancer is responding. The study involves a dose-finding phase followed by a larger expansion phase, and your participation may last several months or longer depending on how well you respond.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Testing a new cancer treatment alone and with other immunotherapies

What is this trial?

Do you qualify?

What participation looks like

Trial locations(64 sites)